Alpha vs Beta Emitters: How Isotope Choice Changes Radioligand Target Selection

Updated October 2026.

Most target-selection frameworks treat the isotope as a later decision: find a good target first, then pick a payload. In practice the two are coupled. A target that works well with ¹⁷⁷Lu can fail with ²²⁵Ac, and the reverse is also true. The physics of each emitter changes which tumor and normal-tissue properties matter most.

This guide sets out those differences and what they mean when you shortlist targets.

The physics in one table

Two numbers drive almost everything else: range and linear energy transfer (LET). A beta particle deposits a little energy over a millimetre, so a single bound molecule irradiates dozens of neighbouring cells (the "crossfire" effect). An alpha particle deposits a lot of energy over a few cells, so it can kill the cell it binds, and its immediate neighbours, with very few hits, but almost nothing beyond them.

Six ways the isotope changes what makes a good target

1. Expression homogeneity

Beta emitters tolerate heterogeneous expression. Because crossfire covers roughly a millimetre, antigen-negative cells near positive cells still receive dose. A target positive in 60% of cells in a patchy pattern can still work with ¹⁷⁷Lu.

Alpha emitters need homogeneous expression. Cells more than a few diameters from a bound radioligand are essentially untreated. For alpha programs, the share of positive cells in each lesion matters more than average intensity. When you read immunohistochemistry, look at the percentage of positive tumor cells, not just the staining score.

2. Antigen density

Because a few alpha traversals can kill a cell, alpha emitters can work at lower antigen density than beta emitters. That reopens targets that were dismissed for ¹⁷⁷Lu because tumor uptake was too low to reach a therapeutic absorbed dose. It also explains why ²²⁵Ac-PSMA agents have produced responses in some patients whose disease progressed on ¹⁷⁷Lu-PSMA.

3. Internalization

Internalization helps every radioligand by retaining activity in the tumor. For ²²⁵Ac, it is close to essential. Each alpha decay gives the daughter nucleus enough recoil energy to break free of any chelator. Daughters released at the cell surface can enter the circulation and accumulate elsewhere, especially in the kidney (²¹³Bi). Daughters released inside an internalizing cell are far more likely to stay there. When the isotope is ²²⁵Ac, rank internalizing targets above non-internalizing ones.

4. Tumor burden and size

Beta suits bulky disease, where crossfire compensates for poor penetration and heterogeneous uptake. Alpha suits micrometastatic, minimal-residual and marrow-based disease, where the targets are single cells or small clusters and the energy from a beta particle would mostly be deposited outside the tumor. If the indication is adjuvant, or the disease is diffuse in bone marrow, alpha targets deserve more weight.

5. Normal-tissue tolerance

High-LET radiation is less forgiving in normal tissue. With ²²⁵Ac-PSMA-617, xerostomia from salivary gland uptake has been dose-limiting in a way it was not with the ¹⁷⁷Lu version. Kidney dose comes both from target expression and from daughter redistribution that target expression data cannot predict.

So for an alpha program, apply a stricter normal-tissue bar in kidney, salivary glands and bone marrow, and treat any expression in those organs as a stronger negative. See how normal-tissue expression maps to dosimetry risk.

6. Vector half-life

The isotope's half-life should match how long the vector takes to reach and stay in the tumor:

• Full-length antibodies circulate for days. They pair with long-lived isotopes (²²⁵Ac, ¹⁷⁷Lu, ²²⁷Th), but long circulation means more bone marrow exposure.
• Peptides and small molecules reach the tumor within hours and clear fast. They pair well with ¹⁷⁷Lu, and with the short-lived ²¹²Pb.

The target constrains the vector: a target with a small or complex extracellular domain may only be reachable with an antibody, which then constrains the isotope. For multi-pass membrane proteins, check early whether a peptide or small-molecule binder is realistic.

A practical rule of thumb

Screen targets for your isotope. Nuclens scores every cell-surface target on tumor expression and positivity, internalization, shedding and clinical precedent, so you can weight them for an alpha or beta program. Rank targets for an actinium-225 program free →

Where to go next

• The full framework: what makes a good radioligand therapy target.
• Targets that are attracting alpha programs: emerging radioligand targets beyond PSMA and targets for PSMA-low prostate cancer.
• Every candidate ranked by cancer type: radioligand therapy targets by cancer.

Nuclens is a first-pass triage tool. It doesn't replace dosimetry, wet-lab validation or clinical judgement.

Rank targets for a lutetium-177 program free →